RICHMOND, Calif., September 12, 2017 — Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Thomas Looby, the company’s President and Chief Executive Officer, will be a keynote speaker on September 14th at WearRAcon China, which is being held in conjunction with the China Disabled Persons’ Federation Conference at the National Convention Center in Beijing, China from September 13-15, 2017.
During the keynote address, Mr. Looby will provide a corporate overview of the Company’s medical division, EksoHealth, including clinical benefits of the EksoGT™, a wearable exoskeleton device designed for stroke and spinal cord injury rehabilitation. In addition, the presentation will highlight the Company’s EksoWorks products, like the EksoZeroG™ and EksoVest™, which are designed to offer construction and industrial workers protection and support against fatigue and injury by reducing the strain from high-frequency and long-duration activities.
“We are thrilled to be presenting at WearRAcon in China, which provides Ekso Bionics with visibility in a country with the world’s largest number of stroke and spinal cord injury patients,” said Mr. Looby. “The EksoGT enables mobility for patients earlier in their recovery process than conventional rehabilitation, so this conference marks an important milestone towards our goal of changing lives around the world with our proprietary exoskeleton technologies.”
WearRAcon is an annual event organized by the Wearable Robotics Association (WearRA), the only professional association dedicated to entrepreneurs, businesses and academics fueling the wearable robotics industry. WearRAcon China will bring together more than 300 attendees from across the world to attend cutting-edge presentations and robotics demonstrations, as well as provide opportunities to network with those creating and using wearable robotic devices in the quickly growing Asian market.
The China Disabled Persons’ Federation, established in 1988, is a national umbrella organization for persons with diverse disabilities. The organization’s mission is to promote the full participation of persons with disabilities in society equally with others, ensure that persons with disabilities share in the material and cultural achievements of society, and foster humanitarianism across society as a whole.
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of a patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 185 rehabilitation institutions around the world.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the period and year ended December 31, 2016, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Annual Report on Form 10-K that are required to be included therein, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.